Global Recombinant Human M-CSF Protein Market Growth (Status and Outlook) 2025-2031
Description
The global Recombinant Human M-CSF Protein market size is predicted to grow from US$ 161 million in 2025 to US$ 268 million in 2031; it is expected to grow at a CAGR of 8.8% from 2025 to 2031.
Macrophage colony stimulating factor (M-CSF) is a potent hematopoietic factor produced by a variety of cells, including lymphocytes, monocytes, fibroblasts, endothelial cells, myoblasts, and osteoblasts. It is a key regulator of proliferation, differentiation, and survival of blood monocytes, tissue macrophages, and their respective progenitors. M-CSF has been shown to play an important role in regulating skin thickness and fertility. M-CSF is used clinically to treat infections, malignancies, and atherosclerosis. It helps hematopoietic recovery after bone marrow transplantation.
United States market for Recombinant Human M-CSF Protein is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.
China market for Recombinant Human M-CSF Protein is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.
Europe market for Recombinant Human M-CSF Protein is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.
Global key Recombinant Human M-CSF Protein players cover Novartis, Amgen, Betta Pharmaceuticals, Thermo Fisher Scientific Inc., Eli Lilly and Company, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2024.
LPI (LP Information)' newest research report, the “Recombinant Human M-CSF Protein Industry Forecast” looks at past sales and reviews total world Recombinant Human M-CSF Protein sales in 2024, providing a comprehensive analysis by region and market sector of projected Recombinant Human M-CSF Protein sales for 2025 through 2031. With Recombinant Human M-CSF Protein sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Recombinant Human M-CSF Protein industry.
This Insight Report provides a comprehensive analysis of the global Recombinant Human M-CSF Protein landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Recombinant Human M-CSF Protein portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Recombinant Human M-CSF Protein market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Recombinant Human M-CSF Protein and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Recombinant Human M-CSF Protein.
This report presents a comprehensive overview, market shares, and growth opportunities of Recombinant Human M-CSF Protein market by product type, application, key players and key regions and countries.
Segmentation by Type:
Purity＞95%
Purity≤95%
Segmentation by Application:
Medical and Biological Laboratories
University Laboratories
Others
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Novartis
Amgen
Betta Pharmaceuticals
Thermo Fisher Scientific Inc.
Eli Lilly and Company
Bio-Techne
Merck
Yeasen
Sino Biological
Miltenyi Biotec
Proteintech
BioLegend
Please note: The report will take approximately 2 business days to prepare and deliver.
Macrophage colony stimulating factor (M-CSF) is a potent hematopoietic factor produced by a variety of cells, including lymphocytes, monocytes, fibroblasts, endothelial cells, myoblasts, and osteoblasts. It is a key regulator of proliferation, differentiation, and survival of blood monocytes, tissue macrophages, and their respective progenitors. M-CSF has been shown to play an important role in regulating skin thickness and fertility. M-CSF is used clinically to treat infections, malignancies, and atherosclerosis. It helps hematopoietic recovery after bone marrow transplantation.
United States market for Recombinant Human M-CSF Protein is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.
China market for Recombinant Human M-CSF Protein is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.
Europe market for Recombinant Human M-CSF Protein is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.
Global key Recombinant Human M-CSF Protein players cover Novartis, Amgen, Betta Pharmaceuticals, Thermo Fisher Scientific Inc., Eli Lilly and Company, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2024.
LPI (LP Information)' newest research report, the “Recombinant Human M-CSF Protein Industry Forecast” looks at past sales and reviews total world Recombinant Human M-CSF Protein sales in 2024, providing a comprehensive analysis by region and market sector of projected Recombinant Human M-CSF Protein sales for 2025 through 2031. With Recombinant Human M-CSF Protein sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Recombinant Human M-CSF Protein industry.
This Insight Report provides a comprehensive analysis of the global Recombinant Human M-CSF Protein landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Recombinant Human M-CSF Protein portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Recombinant Human M-CSF Protein market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Recombinant Human M-CSF Protein and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Recombinant Human M-CSF Protein.
This report presents a comprehensive overview, market shares, and growth opportunities of Recombinant Human M-CSF Protein market by product type, application, key players and key regions and countries.
Segmentation by Type:
Purity＞95%
Purity≤95%
Segmentation by Application:
Medical and Biological Laboratories
University Laboratories
Others
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Novartis
Amgen
Betta Pharmaceuticals
Thermo Fisher Scientific Inc.
Eli Lilly and Company
Bio-Techne
Merck
Yeasen
Sino Biological
Miltenyi Biotec
Proteintech
BioLegend
Please note: The report will take approximately 2 business days to prepare and deliver.
Table of Contents
115 Pages
- *This is a tentative TOC and the final deliverable is subject to change.*
- 1 Scope of the Report
- 2 Executive Summary
- 3 Recombinant Human M-CSF Protein Market Size by Player
- 4 Recombinant Human M-CSF Protein by Region
- 5 Americas
- 6 APAC
- 7 Europe
- 8 Middle East & Africa
- 9 Market Drivers, Challenges and Trends
- 10 Global Recombinant Human M-CSF Protein Market Forecast
- 11 Key Players Analysis
- 12 Research Findings and Conclusion
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
